Customer Case: Development of new IL-25 antibody drugs for atopic dermatitis (AD).

Client: A pharmaceutical company is developing a novel antibody targeting the IL-25 pathway for the treatment of AD

Objective: To determine the efficacy and safety of a novel anti-IL-25 antibody in a preclinical model of atopic dermatitis compared with a standard positive control.

Methodology:

1. Select the appropriate AD model: Given the client's in-depth understanding of the IL-25 pathway and AD pathogenesis, the MC903-induced AD mouse model was selected because of its ability to mimic key aspects of human AD pathology and cytokine profiles.

2. Selection of positive control drug: Crisaborole was selected as a positive control because of its established efficacy in reducing AD symptoms and modulating immune responses.

Experimental design:

-The animals were divided into four groups: normal group, vehicle group, positive control group (Crisaborole), anti-IL-25 antibody low-dose group and high-dose group.

- Treatment duration is set at 3 weeks and is administered topically to mimic topical treatment.

Evaluation parameters:

Clinical Assessment: Assess the severity of dermatitis, erythema, and pruritus using a standardized scoring system.

Skin tissue analysis: Skin biopsies were subjected to histological examination of epidermal hyperplasia, inflammatory cell infiltration, and cytokine expression levels.

Molecular analysis: Analyze key inflammatory mediators and immune cell populations in the skin at the molecular level, focusing on the IL-25 downstream signaling pathway.

Pathological analysis: Assess skin barrier function, keratinocyte proliferation, and proinflammatory cytokine expression within skin lesions.

result:

-The results showed that clinical symptoms, inflammatory cell infiltration, and cytokine expression were significantly reduced in the anti-IL-25 antibody group compared with the vehicle group and the positive control group, indicating that anti-IL-25 antibodies have excellent efficacy in the treatment of atopic dermatitis.

in conclusion:

Through comprehensive evaluation at the clinical, cellular and , molecular and pathological levels, the novel anti-IL-25 antibody shows promising potential in the treatment of atopic dermatitis and represents a major advance in the field of dermatology.